Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase

被引:53
作者
Shen, Jin-Song [1 ]
Edwards, Nancy J. [1 ]
Bin Hong, Young [1 ]
Murray, Gary J. [1 ]
机构
[1] Natl Inst Neurol Disorders & Stroke, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
关键词
pharmacological chaperone; Gaucher disease; lysosomal storage disorders; glucocerebrosidase; molecular chaperone; molecular mechanisms of pharmacological action; enzyme replacement therapy;
D O I
10.1016/j.bbrc.2008.02.125
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Intravenous enzyme replacement therapy (ERT) with purified glucocerebrosidase (GLA) leads to significant improvement of the clinical manifestations in patients with Type 1 Gaucher disease. However, the high doses required, slow response and inability to recover most of the infused enzyme in the target tissues may be attributed to losses occurring during transit en route to the lysosome. Preincubation of GLA with isofagomine (IFG), a slow-binding inhibitor, significantly increased stability of the enzyme to heat, neutral pH and denaturing agents in vitro. Preincubation of GLA with isofagomine prior to uptake by cultured cells results in increased intracellular enzyme activity accompanied by an increase in enzyme protein suggesting that reduced denaturation of GLA in the presence of isofagomine leads to a decrease in the degradation of the enzyme after internalization. Preincubation of GLA with slow-binding inhibitors before infusion may improve the effectiveness of ERT for Gaucher disease. Published by Elsevier Inc.
引用
收藏
页码:1071 / 1075
页数:5
相关论文
共 23 条
[1]  
Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
[2]   Enzyme replacement for lysosomal diseases [J].
Brady, RO .
ANNUAL REVIEW OF MEDICINE, 2006, 57 :283-296
[3]   METABOLISM OF GLUCOCEREBROSIDES .2. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHERS DISEASE [J].
BRADY, RO ;
KANFER, JN ;
SHAPIRO, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1965, 18 (02) :221-&
[4]   Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients [J].
Chang, Hui-Hwa ;
Asano, Naoki ;
Ishii, Satoshi ;
Ichikawa, Yoshitaka ;
Fan, Jian-Qiang .
FEBS JOURNAL, 2006, 273 (17) :4082-4092
[5]   SOLUBILIZATION OF GLUCOCEREBROSIDASE FROM HUMAN PLACENTA AND DEMONSTRATION OF A PHOSPHOLIPID REQUIREMENT FOR ITS CATALYTIC ACTIVITY [J].
DALE, GL ;
VILLACORTE, DG ;
BEUTLER, E .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1976, 71 (04) :1048-1053
[6]   Enzyme replacement and enhancement therapies for lysosomal diseases [J].
Desnick, RJ .
JOURNAL OF INHERITED METABOLIC DISEASE, 2004, 27 (03) :385-410
[7]   GENERATION OF MACROPHAGE VARIANTS WITH 5-AZACYTIDINE - SELECTION FOR MANNOSE RECEPTOR EXPRESSION [J].
DIMENT, S ;
LEECH, MS ;
STAHL, PD .
JOURNAL OF LEUKOCYTE BIOLOGY, 1987, 42 (05) :485-490
[8]  
Grabowski Gregory A, 2006, Expert Opin Drug Deliv, V3, P771, DOI 10.1517/17425247.3.6.771
[9]   HUMAN ACID BETA-GLUCOSIDASE - USE OF SPHINGOSYL AND N-ALKYL-GLUCOSYLAMINE INHIBITORS TO INVESTIGATE THE PROPERTIES OF THE ACTIVE-SITE [J].
GREENBERG, P ;
MERRILL, AH ;
LIOTTA, DC ;
GRABOWSKI, GA .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1039 (01) :12-20
[10]   Substrate reduction therapy for glycosphingolipid storage disorders [J].
Lachmann, RH ;
Platt, FM .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (03) :455-466